Compare SSRM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSRM | RYTM |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.9B |
| IPO Year | N/A | 2017 |
| Metric | SSRM | RYTM |
|---|---|---|
| Price | $31.48 | $86.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $32.74 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 4.0M | 934.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.07 | $55.17 |
| Revenue Next Year | $3.57 | $95.98 |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.65 | $45.91 |
| 52 Week High | $33.49 | $122.20 |
| Indicator | SSRM | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 47.22 |
| Support Level | $21.71 | $84.39 |
| Resistance Level | $33.49 | $97.19 |
| Average True Range (ATR) | 1.78 | 5.47 |
| MACD | 0.54 | 0.58 |
| Stochastic Oscillator | 88.56 | 46.24 |
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.